IgA nephropathy at two score and one

Kidney International

Volumn 77, Issue 3, 2010, Pages 181-186

  Coppo, Rosanna ^a   Feehally, John ^b   Glassock, Richard J ^c  

^a REGINA MARGHERITA CHILDREN S HOSPITAL   (Italy)

^b LEICESTER GENERAL HOSPITAL   (United Kingdom)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Galactose deficient IgA; IgA nephropathy; IgA subclass 1; Renal biopsy

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; AZATHIOPRINE; CYCLOPHOSPHAMIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GLUCOCORTICOID; METHYLPREDNISOLONE;

ANAPHYLACTOID PURPURA; CLINICAL TRIAL; CONFERENCE PAPER; DISEASE COURSE; DISEASE SEVERITY; GENETICS; GLOMERULOPATHY; GLYCOSYLATION; HUMAN; IMMUNOGLOBULIN A NEPHROPATHY; ITALY; KIDNEY FAILURE; MONOTHERAPY; PATHOGENESIS; PLASMAPHERESIS; PRIORITY JOURNAL; PROGNOSIS; PROTEINURIA; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 74449089817     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2009.427     Document Type: Conference Paper

References (35)

1. D'Amico G. The commonest glomerulonephritis in the world: IgA nephropathy. Q J Med 1987; 64: 709-727.
2. Suzuki K, Honda K, Tanabe K et al. Incidence of latent mesangial IgA deposition in renal allograft donors in Japan. Kidney Int 2003; 63: 2286-2294.
3. Tomino Y. IgA nephropathy: lessons from an animal model, the ddY mouse. J Nephrol 2008; 21: 463-467.
4. Kerr MA. The structure and function of human IgA. Biochem J 1990; 271: 285-296.
5. Coppo R, Amore A, Gianoglio B et al. Serum IgA and macromolecular IgA reactive with mesangial matrix components. In: Bené MC, Faure GC, Kessel M (eds). Contribution of Nephrology IgA Nephropathy: the 24th year. Karger: Basel, 1993, pp 162-172.
6. Terai I, Kobayashi K, Vaerman JP et al. Degalactosylated and/or denatured IgA, but not native IgA in any form, bind to mannose-binding lectin. J Immunol 2006; 177: 1737-1745.
7. Gharavi AG, Moldoveanu Z, Wyatt RJ et al. Aberrant IgA1 glycosylation is inherited in familial and sporadic IgA nephropathy. J Am Soc Nephrol 2008; 19: 1008-1014.
8. Li GS, Zhang H, Lv JC et al. Variants of C1GALT1 gene are associated with the genetic susceptibility to IgA nephropathy. Kidney Int 2007; 71: 448-453.
9. Malycha F, Eggermann T, Hristov M et al. No evidence for a role of cosmc-chaperone mutations in European IgA nephropathy patients. Nephrol Dial Transplant 2009; 24: 321-324.
10. Allen AC, Bailey EM, Barratt J et al. Analysis of IgA1 O-glycans in IgA nephropathy by fluorophore-assisted carbohydrate electrophoresis. J Am Soc Nephrol 1999; 10: 1763-1771.
11. Hiki Y, Tanaka A, Kokubo T et al. Analyses of IgA1 hinge glyco-peptides in IgA nephropathy by matrix-assisted laser desorption/ ionization time-of-flight mass spectrometry. J Am Soc Nephrol 1998; 9: 577-582.
12. Mestecky J, Tomana M, Moldoveanu Z et al. Role of aberrant glycosylation of IgA1 molecules in the pathogenesis of IgA nephropathy. Kidney Blood Press Res 2008; 31: 29-37.
13. Suzuki H, Moldoveanu Z, Hall S et al. IgA1-secreting cell lines from patients with IgA nephropathy produce aberrantly glycosylated IgA1. J Clin Invest 2008; 118: 629-639.
14. Suzuki H, Fan R, Zhang Z et al. Aberrantly glycosylated IgA1 in IgA nephropathy patients is recognized by IgG antibodies with restricted heterogeneity. J Clin Invest 2009; 119: 1668-1677.
15. Buck KS, Smith AC, Molyneux K et al. B-cell O-galactosyltransferase activity, and expression of O-glycosylation genes in bone marrow in IgA nephropathy. Kidney Int 2008; 73: 1128-1136.
16. Monteiro RC. Pathogenic role of IgA receptors in IgA nephropathy. Contrib Nephrol 2007; 157: 64-69.
17. Oortwijn BD, Rastaldi MP, Roos A et al. Demonstration of secretory IgA in kidneys of patients with IgA nephropathy. Nephrol Dial Transplant 2007; 22: 3191-3195.
18. Lai KN, Leung JC, Chan LY et al. Activation of podocytes by mesangial-derived TNF-alpha: glomerulo-podocytic communication in IgA nephropathy. Am J Physiol Renal Physiol 2008; 294: F945-F955.
19. Roberts ISD, Cook HT, Troyanov S et al. Working Group of the International IgA Nephropathy Network and the Renal Pathology Society. The Oxford Classification of IgA Nephropathy: Rationale, clinicopathological correlations, and proposal for classification. Kidney Int 2009; 76: 534-545.
20. Cattran D, Coppo R, Cook TH et al. Working Group of the International IgA Nephropathy Network and the Renal Pathology Society The Oxford Classification of IgA Nephropathy: Pathology definitions, correlations and reproducibility. Kidney Int 2009; 76: 546-556.
21. van Es LA, de Heer E, Vleming LJ et al. GMP-17-positive T-lymphocytes in renal tubules predict progression in early stages of IgA nephropathy. Kidney Int 2008; 73: 1426-1433.
22. Harada K, Akai Y, Yamaguchi Y et al. Prediction of corticosteroid responsiveness based on fibroblast-specific protein 1 (FSP1) in patients with IgA nephropathy. Nephrol Dial Transplant 2008; 23: 3152-3159.
23. Rocchetti MT, Centra M, Papale M et al. Urine protein profile of IgA nephropathy patients may predict the response to ACE-inhibitor therapy. Proteomics 2008; 8: 206-216.
24. Praga M, Gutiérrez E, González E et al. Treatment of IgA nephropathy with ACE inhibitors: a randomized and controlled trial. J Am Soc Nephrol 2003; 14: 1578-1583.
25. Coppo R, Peruzzi L, Amore A et al. IgACE: a placebo-controlled, randomized trial of angiotensin-converting enzyme inhibitors in children and young people with IgA nephropathy and moderate proteinuria. J Am Soc Nephrol 2007; 18: 1880-1888.
26. Russo D, Minutolo R, Pisani A et al. Coadministration of losartan and enalapril exerts additive antiproteinuric effect in IgA nephropathy. Am J Kidney Dis 2001; 38: 18-25.
27. Horita Y, Tadokoro M, Taura K et al. Low-dose combination therapy with temocapril and losartan reduces proteinuria in normotensive patients with immunoglobulin a nephropathy. Hypertens Res 2004; 27: 963-970.
28. Pozzi C, Andrulli S, Del Vecchio L et al. Corticosteroid effectiveness in IgA nephropathy: long-term results of a randomized, controlled trial. J Am Soc Nephrol 2004; 15: 157-163.
29. Eitner F, Ackermann D, Hilgers RD et al. Supportive versus immunosuppressive therapy of progressive IgA nephropathy (STOP) IgAN trial: rationale and study protocol. J Nephrol 2008; 21: 284-289.
30. Ballardie FW, Roberts IS. Controlled prospective trial of prednisolone and cytotoxics in progressive IgA nephropathy. J Am Soc Nephrol 2002; 13: 142-148.
31. Xie Y, Nishi S, Ueno M et al. The efficacy of tonsillectomy on long-term renal survival in patients with IgA nephropathy. Kidney Int 2003; 63: 1861-1867.
32. Komatsu H, Fujimoto S, Hara S et al. Effect of tonsillectomy plus steroid pulse therapy on clinical remission of IgA nephropathy: a controlled study. Clin J Am Soc Nephrol 2008; 3: 1301-1307.
33. Ponticelli C, Traversi L, Feliciani A et al. Kidney transplantation in patients with IgA mesangial glomerulonephritis. Kidney Int 2001; 60: 1948-1954.
34. Wang AY, Lai FM, Yu AW et al. Recurrent IgA nephropathy in renal transplant allografts. Am J Kidney Dis 2001; 38: 588-596.
35. Coppo R, Amore A, Chiesa M et al. Serological and genetic factors in early recurrence of IgA nephropathy after renal transplantation. Clin Transplant 2007; 21: 728-737.